Beam Therapeutics
Business Services · Massachusetts, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
238 Main St, Cambridge, Massachusetts, 0...Phone Number
(857) 327-8775Website
www.beamtx.comRevenue
$164 MillionStock Symbol
BEAMIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
5
5
2
2
2
About Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing. The company advances research and clinical programs aimed at providing durable treatments for serious diseases, supported by scientific leadership and drug development capabilities. Beam focuses on translating genome editing science into potential lifelong therapies for patients.Explore more
Beam Therapeutics Org Chart
AW
Senior VP, Regulatory Affairs & Quality
SR
Vice President, Legal
LJ
Vice President, Corporate Counsel
EC
Head Vice President, Intellectual Property
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Beam Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Beam Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Beam Therapeutics is spiking on competitors!
Earning: See what the market has to say on Beam Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Beam Therapeutics has new funding data
Product Launch: Get notified when Beam Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Beam Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Beam Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Beam Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Beam Therapeutics
Compare insights from companies similar to Beam Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Beam Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Beam Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Beam Therapeutics.
Beam Therapeutics financials insights
Gather financial insights about Beam Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$87M
2019
Series B
$135M
2020
Stock Offering
$207M
Stock Offering
$117.5M
2021
Share Placement
$260M
2026
Debt
$500M
Beam Therapeutics Tech Stack
A closer look at the technologies used by Beam Therapeutics
See more technologies
Most Recent Scoops
Hiring Plans
Beam Therapeutics has more open roles in Finance than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Beam Therapeutics News & Media
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
Beam Therapeutics' growing pipeline could reward patient investors.Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKUTwo Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock
Beam Therapeutics Inc (NASDAQ:BEAM) is one of the best gene therapy stocks to buy in 2026. The stock is up roughly 27% in the past six months and soared more than 60% in the past year. The Street expects BEAM stock to pop almost 70% in the next 12 months as therapy programs continue to […]Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Beam Therapeutics
Sign Up For FreeTo access detailed company insights
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing. The company advances research and clinical programs aimed at providing durable treatments for serious diseases, supported by scientific leadership and drug development capabilities. Beam focuses on translating genome editing science into potentia... Read More
